Sinovac Biotech Ltd. develops, manufactures and commercializes vaccines and related biological products for human infectious diseases. The China-based biopharmaceutical company’s marketed portfolio includes vaccines for influenza, viral hepatitis, varicella, hand-foot-mouth disease associated with EV71, poliomyelitis, pneumococcal disease and COVID-19, and its pipeline includes combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Company updates commonly address vaccine sales, research and development progress, product approvals, overseas market activity and financial reporting. Recent corporate developments also include Nasdaq listing-compliance matters, auditor engagement, SEC filing status and governance proceedings involving board composition and shareholder-meeting disputes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sinovac Biotech Ltd. (SVA) announced an amendment to its shareholder rights plan, extending its expiration from February 22, 2023, to February 22, 2024. The company, based in China, specializes in developing and manufacturing vaccines for infectious diseases, including COVID-19, hepatitis A, and enterovirus 71. Notably, Sinovac's COVID-19 vaccine, CoronaVac®, is approved in over 60 countries. The firm is committed to ongoing research and exploration of global market opportunities to enhance its product offerings.
Sinovac Biotech Ltd. (NASDAQ: SVA) reported its unaudited financial results for the first half of 2022, showing a significant decline in sales to $1.2 billion from $11.0 billion the previous year. Net income attributable to common shareholders was $481.6 million ($4.84 per share), down from $5.1 billion ($51.42 per share) in the same period last year. Despite the decline, Sinovac's non-COVID vaccine sales grew by 37%. The company is heavily investing in R&D for various COVID-19 vaccines and has gained multiple WHO approvals for its products, expanding its global market reach.